Nutraceuticals for Cardiometabolic Diseases: Prophylactic and Therapeutic Research
A special issue of Nutraceuticals (ISSN 1661-3821).
Deadline for manuscript submissions: 31 December 2024 | Viewed by 14860
Special Issue Editor
Interests: cardiovascular diseases; inflammation; circadian rhythms; dietary supplements; nutraceuticals; aging; exercise; preventative medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular diseases are the leading cause of death worldwide. A maladaptive diet and lifestyle are key contributors to the development of metabolic risk factors such as obesity as well as high blood pressure, high glucose, and high cholesterol levels, which are associated with the development of cardiometabolic diseases. Although prophylactics and therapeutics are available for prevention and treatment, there is a growing market of dietary supplements and nutraceuticals purporting to be of benefit against cardiometabolic diseases and related risk factors.
Dietary supplements and nutraceuticals are related but distinct nonpharmaceutical products. Nutraceuticals are supplements with purported health benefits that exceed their basic nutritional value. Therefore, the main difference between a nutraceutical and a dietary supplement is that nutraceuticals should not only supplement the diet, but should also contribute to the prophylaxis or treatment of a diseases or disorder. However, defining nutraceuticals is a challenge, so manuscripts describing supplements with potential prophylactic or therapeutic effects are also welcome.
This Special Issue is focused on nutraceuticals and supplements for the prevention and treatment of cardiometabolic diseases. Original articles and reviews aimed at understanding the molecular mechanisms that underpin the actions of nutraceuticals on cardiometabolic disesases are welcome. These include studies relating to atherosclerosis, inflammation, obesity, immune function, platelet function, cholesterol metabolism, and diabetes. In particular, human studies investigating the efficacy of nutraceuticals as preventative and/or therapeutic agents are welcome. Potential topics include but are not limited to nutraceutical actions in cultured cells, animal models, and human subjects that address aspects such as cellular responses, signal transduction, gene expression, intracellular targets, biomarkers and disease severity, and bioavailability among other topics will be considered. Articles related to nutraceutical development, regulation, and market growth are also welcome.
Dr. Ronan Lordan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutraceuticals is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nutraceuticals
- supplements
- natural products
- cardiovascular diseases
- atherosclerosis
- inflammation
- blood pressure
- obesity
- metabolism
- diabetes
- oxidative stress
- nutraceutical regulation
- nutraceutical markets
- nutraceutical efficacy
- nutraceutical safety
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Bioactivity of carrageenan in metabolic syndrome and cardiovascular diseases
Author: Ana Valado
Abstract: The high incidence of changes in the lipid profile in the world population is supported by the adoption of a lifestyle with numerous risk factors. Dyslipidemia, the main alteration in the lipid profile, is characterized by increased concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and decreased high-density lipoprotein cholesterol (HDL-C). These modifications in lipid metabolism are particularities of Metabolic Syndrome (MetS) and one of the main risk factors for the development of cardiovascular diseases (CVDs), one of the main causes of death in the world. Macroalgae are marine photosynthetic organisms, which have a high percentage of vitamins, minerals, dietary fiber, and a low percentage of lipids. Thus, the ingestion of macroalgae or their components constitutes a benefit for human health. Carrageenan (E407), a long-chain polysaccharide extracted from the macroalgae of the phylum Rhodophyta, is present in several foods, such as jelly of vegetable origin. Chemically, it presents several structures with different applications and purposes in the cosmetic, food, and pharmaceutical industries. According to some investigations, the bioactive potential of carrageenan was demonstrated in the reduction of the levels of parameters of the lipidic profile, being able to be an alternative in the reversion of MetS and, consequently, in the prevention and treatment of CVDs. This review article aims to compile, evaluate, and reflect on the effect of carrageenan on lipid profile markers (TC, TG, HDL-C, LDL-C), relating them to MetS and CVDs.
Keywords: Carrageenan, dyslipidemia, TC, HDL-C, LDL-C, TG, Metabolic Syndrome, CVDs